Literature DB >> 16831915

The regulation of cathepsin K gene expression.

Bruce R Troen1.   

Abstract

Cathepsin K is essential for normal bone resorption. Osteoclasts synthesize and secrete cathepsin Kinto the extracellular compartment at the attachment site between osteoclasts and the bone surface, wherein the organic matrix is subsequently degraded by cathepsin K. RANKL, NFAT, Mitf, and various components of AP-1 enhance osteoclast formation and bone resorption, whereas IFN-gamma, calcitonin, estradiol, and calcium inhibit it. These agents appear to act correspondingly to alter cathepsin K mRNA and protein expression in order to stimulate and suppress the osteoclast's resorbing potential. RANKL signaling via the calcineurin-calcium-NFAT signaling cascade plays a significant role in the regulation of cathepsin K expression. Activation via p38 and the micropthalmia transcription factor also enhances cathepsin K expression. Future studies will be needed to elucidate the relative roles of various signaling pathways at different stages of osteoclast formation and activation and to determine whether genetically disrupting these pathways can modulate bone resorption with or without impeding other osteoclast functions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16831915     DOI: 10.1196/annals.1346.018

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  41 in total

1.  Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone.

Authors:  Angela C Hirbe; Jessica Rubin; Ozge Uluçkan; Elizabeth A Morgan; Mark C Eagleton; Julie L Prior; David Piwnica-Worms; Katherine N Weilbaecher
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-22       Impact factor: 11.205

2.  Aging and bone loss: new insights for the clinician.

Authors:  Oddom Demontiero; Christopher Vidal; Gustavo Duque
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-04       Impact factor: 5.346

Review 3.  Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis.

Authors:  Aline G Costa; Natalie E Cusano; Barbara C Silva; Serge Cremers; John P Bilezikian
Journal:  Nat Rev Rheumatol       Date:  2011-06-14       Impact factor: 20.543

4.  Regulation of osteoclasts by osteoblast lineage cells depends on titanium implant surface properties.

Authors:  Ethan M Lotz; Michael B Berger; Zvi Schwartz; Barbara D Boyan
Journal:  Acta Biomater       Date:  2017-12-30       Impact factor: 8.947

5.  Activation of the vitamin D receptor selectively interferes with calcineurin-mediated inflammation: a clinical evaluation in the abdominal aortic aneurysm.

Authors:  Arend Jan Nieuwland; Vivianne Bc Kokje; Olivier H Koning; Jaap F Hamming; Karoly Szuhai; Frans H J Claas; Jan H N Lindeman
Journal:  Lab Invest       Date:  2016-05-30       Impact factor: 5.662

6.  Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation.

Authors:  Le T Duong
Journal:  Bonekey Rep       Date:  2012-05-02

7.  Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence.

Authors:  Cristiano A F Zerbini; Michael R McClung
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

Review 8.  Understanding and targeting osteoclastic activity in prostate cancer bone metastases.

Authors:  J L Sottnik; E T Keller
Journal:  Curr Mol Med       Date:  2013-05       Impact factor: 2.222

Review 9.  Osteopetrosis.

Authors:  Zornitza Stark; Ravi Savarirayan
Journal:  Orphanet J Rare Dis       Date:  2009-02-20       Impact factor: 4.123

10.  Receptor activator of nuclear factor-kappaB ligand-induced nuclear factor of activated T cells (C1) autoregulates its own expression in osteoclasts and mediates the up-regulation of tartrate-resistant acid phosphatase.

Authors:  Jackie A Fretz; Nirupama K Shevde; Sujay Singh; Bryant G Darnay; J Wesley Pike
Journal:  Mol Endocrinol       Date:  2007-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.